🔥 Trending Manipal Health Enterprises IPO: Latest Updates and Subscription Guide

The Manipal Health Enterprises (MHE) Initial Public Offering (IPO) is a significant event in the Indian primary market, with the company aiming to raise a substantial amount of capital. Here's the latest news and subscription information as of July 29, 2026.

Manipal Health Enterprises IPO Overview

Manipal Health Enterprises is one of India's largest private healthcare providers. As of March 31, 2026, it operates a pan-India network of 49 multispecialty hospitals with 13,037 licensed beds across 14 states and union territories ⁷. The company is bringing its IPO to the market to reduce debt and fund acquisitions ⁴.

Key Dates and Price Details

The Manipal Health Enterprises IPO opened for subscription on July 29, 2026, and will close on July 31, 2026 ²⁶¹⁰.

• Price Band: The shares are priced between ₹560 and ₹590 per share ²⁵⁹.
• Issue Size: The total IPO aims to raise approximately ₹9,273.64 crores ⁶. This includes a fresh issue of ₹7,998.43 crores and an offer for sale (OFS) of up to 2,16,13,834 equity shares ⁶.
• Valuation: At the upper end of the price band, the company is valued at over ₹77,600 crore ².
• Anchor Investors: Prior to the public opening, Manipal Health Enterprises raised ₹4,167 crore from anchor investors ².

Subscription Status and Grey Market Premium (GMP)

The IPO opened today, July 29, 2026, amidst a busy week for India's primary market, with nine IPOs launching across mainboard and SME segments ¹.

• Grey Market Premium (GMP): The Grey Market Premium (GMP) for Manipal Health Enterprises IPO is currently reported to be around 2% ⁴. This indicates limited listing gains are anticipated by the grey market ⁴.

Brokerage Recommendations

Several brokerages have offered their views on the Manipal Health Enterprises IPO:

• Positive Outlook: SBI Securities and Emkay have given "Subscribe" recommendations, citing the company's market leadership, strong growth prospects, and attractive valuation ⁸.
• Long-term vs. Short-term: While most brokerages recommend subscribing for the long term, some caution about potential muted listing gains due to the low GMP ⁴.

Investors are advised to check the live subscription status and detailed analysis from financial experts before making an investment decision ³.